We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
1.Rascol, O, Brooks, DJ, Korczyn, AD, et al.A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med2000; 342:1484–1491.Google Scholar
2
2.Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson’s disease. A randomized controlled trial. JAMA2000; 284:1931–1938.Google Scholar
3
3.Lees, AJ, Katzenschlager, R, Head, J, Ben Shlomo, Y.Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology2001; 57(9):1687–1694.CrossRefGoogle ScholarPubMed
4
4.Marek, K, Seibyl, J, Shoulson, I, et al.Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson’s disease progression. JAMA2002; 287(13):1653–1661.Google Scholar
5
5.Whone, AL, Remy, P, Davis, MR, et al.The REAL-PETstudy: slower progression in early Parkinson’s disease treated with ropinirole compared with L-dopa. Neurology2002;suppl 3:A82-A-83.Google Scholar
6
6.Sanjiv, CC, Schulzer, M, Mak, E, et al.Daytime somnolence in patients with Parkinson’s disease. Parkinsonism & Related Disorders2001; 7: 283–286.Google Scholar
7
7.Hobson, DE, Lang, AE, Martin, WR, et al.Excessive daytime sleepiness and sudden-onset sleep in Parkinson’s disease: a survey by the Canadian Movement Disorders Group. JAMA2002; 287(4):455–463.Google Scholar
8
8.Guttman, M, Slaughter, PM, Theriault, M-E, DeBoer, DP, Naylor, CD.Parkinsonism in Ontario: physician utilization. Can J Neurol Sci2002;29(3):221–226.Google Scholar
9
9.Rajput, AH.Frequency and cause of Parkinson’s disease. Can J Neurol Sci1992; 19 (Suppl. 1):103–107.Google Scholar